Effects of Ramipril and Rosiglitazone on Cardiovascular and Renal Outcomes in People With Impaired Glucose Tolerance or Impaired Fasting Glucose: Results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial

Effects of Ramipril and Rosiglitazone on Cardiovascular and Renal Outcomes in People With Impaired Glucose Tolerance or Impaired Fasting Glucose: Results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial

Bibliographic Details
Format:	Journal article
Published:	2008

Similar Items

Incidence of diabetes following ramipril or rosiglitazone withdrawal
by: Holman, R, et al.
Published: (2011)

Incidence of diabetes following ramipril or rosiglitazone withdrawal.
by: Investigators, D
Published: (2011)

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.
by: Gerstein, H, et al.
Published: (2006)

Effect of ramipril on the incidence of diabetes.
by: Bosch, J, et al.
Published: (2006)

Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
by: Preiss, D, et al.
Published: (2013)

Rosiglitazone diminishes the high-glucose-induced modulation of 5-fluorouracil cytotoxicity in colorectal cancer cells
by: Lau, Meng Fei, et al.
Published: (2018)

Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
by: Califf, R, et al.
Published: (2008)

Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy.
by: Lachin, J, et al.
Published: (2011)

Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial
by: Preiss, D, et al.
Published: (2012)

Rosiglitazone reduces hepatic fat content
by: Buckingham, R, et al.
Published: (2000)

Effect of valsartan on kidney outcomes in people with impaired glucose tolerance.
by: Currie, G, et al.
Published: (2017)

Proteomic analysis of human adipose tissue after rosiglitazone treatment shows coordinated changes to promote glucose uptake.
by: Ahmed, M, et al.
Published: (2010)

Early detection of impaired glucose tolerance in young adults
by: May, Khin Soe, et al.
Published: (2013)

Noncardiovascular deaths are more common than cardiovascular deaths in patients with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial.
by: Sharma, A, et al.
Published: (2016)

Guidance on rosiglitazone for type 2 diabetes mellitus.
by: Matthews, DR
Published: (2001)

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
by: Kahn, SE, et al.
Published: (2006)

Rosiglitazone-associated fractures in type 2 diabetes
by: Kahn, SE, et al.
Published: (2008)

Comparison of in vivo tests for glucose tolerance in subjects with normal, impaired glucose tolerance and type 2 diabetes
by: Hermans, M, et al.
Published: (1996)

Modeling the oral glucose tolerance test in normal and impaired glucose tolerant states: a population approach
by: Theodorakis, M, et al.
Published: (2016)

A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk
by: Bethel, M, et al.
Published: (2013)

A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk.
by: Bethel, M, et al.
Published: (2013)

Diabetes and impaired glucose tolerance: a review of the epidemiological and trial evidence for their role in cardiovascular risk.
by: Bowman, L, et al.
Published: (2002)

A prospective, double-blinded, randomized trial of Ramipril in asymptomatic aortic stenosis: the RIAS trial
by: Bull, S, et al.
Published: (2013)

International variation in outcomes among people with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the NAVIGATOR Trial.
by: Dos Santos, M, et al.
Published: (2017)

People at increased risk of cardiovascular disease screened for the NAVIGATOR trial frequently have undiagnosed diabetes or impaired glucose tolerance
by: Califf, R, et al.
Published: (2003)

The role of nicotinamide nucleotide transhydrogenase in insulin secretion and impaired glucose tolerance
by: Freeman, H, et al.
Published: (2005)

Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
by: Latini, R, et al.
Published: (2013)

Comparison of medical resources, costs, and health utilities among patients with CHD and impaired glucose tolerance in the Acarbose Cardiovascular Evaluation Trial (ACE)
by: Mc Morrow, L, et al.
Published: (2018)

Rosiglitazone prevents ischaemic injury in the obese Zucker rat heart
by: Sidell, R, et al.
Published: (2001)

'Healthy living' and sulphonylurea therapy have different effects on glucose tolerance and risk factors for vascular disease in subjects with impaired glucose tolerance.
by: Page, R, et al.
Published: (1993)

96 The effect of ramipril on the rate of aortic dilatation in bicuspid aortic valve disease: results from a prospective, double blinded, randomised trial.
by: Loudon, M, et al.
Published: (2014)

Role of the transcription factor sox4 in insulin secretion and impaired glucose tolerance.
by: Goldsworthy, M, et al.
Published: (2008)

Prevalence of diabetes mellitus and impaired glucose tolerance in parents of women with gestational diabetes.
by: McLellan, J, et al.
Published: (1995)

Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis.
by: Yates, T, et al.
Published: (2014)

Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): A cohort analysis
by: Yates, T, et al.
Published: (2014)

The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes.
by: Tan, G, et al.
Published: (2005)

Rosiglitazone treatment improves cardiac efficiency in hearts from diabetic mice.
by: How, O, et al.
Published: (2007)

Guidance on rosiglitazone for type 2 diabetes mellitus [7] (multiple letters)
by: Matthews, DR, et al.
Published: (2001)

Greater reductions in C-reactive protein with rosiglitazone than with glyburide or metformin despite greater weight gain
by: Haffner, S, et al.
Published: (2007)

Hyperglycaemic progression in subjects with impaired glucose tolerance: association with decline in beta cell function.
by: Cook, J, et al.
Published: (1993)